Immunogenicity and persistence of immunity of a quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children

Vaccine

Volumn 34, Issue 36, 2016, Pages 4343-4350

  MacIntyre, C Raina ^a,f   Shaw, Peter ^b   Mackie, Fiona E ^c,d   Boros, Christina ^e   Marshall, Helen ^e   Barnes, Michelle ^a   Seale, Holly ^a   Kennedy, Sean E ^c,d   Moa, Aye ^a   Hayen, Andrew ^a   Chughtai, Abrar Ahmad ^a   O'Loughlin, Edward V ^b   Stormon, Michael ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c SYDNEY CHILDREN'S HOSPITAL   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Adolescents; Cancer; Human Papillomavirus; Immunisation; Immunodeficiency; Vaccine; Warts

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; VIRUS ANTIBODY; WART VIRUS VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CHILD; DISEASE EXACERBATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNITY; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; MULTICENTER STUDY; PRIORITY JOURNAL; SEROCONVERSION; SEROTYPE; VACCINATION; ADOLESCENT; AUSTRALIA; BLOOD; CLINICAL TRIAL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; PRESCHOOL CHILD; TIME FACTOR; VACCINE IMMUNOGENICITY; VIROLOGY;

ADOLESCENT; ANTIBODIES, VIRAL; AUSTRALIA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGENICITY, VACCINE; MALE; PAPILLOMAVIRUS INFECTIONS; SEROCONVERSION; TIME FACTORS; VACCINATION;

EID: 84981332598     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.06.049     Document Type: Article

References (47)

1. [1] Munger, K., Phelps, W.C., Bubb, V., Howley, P.M., Schlegel, R., The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 63:10 (1989), 4417–4421.
2. [2] Munger, K., Baldwin, A., Edwards, K.M., Hayakawa, H., Nguyen, C.L., Owens, M., et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78:21 (2004), 11451–11460.
3. [3] Sinal SH, Woods CR. Human papillomavirus infections of the genital and respiratory tracts in young children. In: Seminars in pediatric infectious diseases, vol. 16(4); 2005 October. p. 306–16.
4. [4] Hama, N., Ohtsuka, T., Yamazaki, S., Detection of mucosal human papilloma virus DNA in bowenoid papulosis, Bowen's disease and squamous cell carcinoma of the skin. J Dermatol 33:5 (2006), 331–337.
5. [5] Yao, P.F., Li, G.C., Li, J., Xia, H.S., Yang, X.L., Huang, H.Y., et al. Evidence of human papilloma virus infection and its epidemiology in esophageal squamous cell carcinoma. World J Gastroenterol: WJG 12:9 (2006), 1352–1355.
6. [6] Carter, J.J., Madeleine, M.M., Shera, K., Schwartz, S.M., Cushing-Haugen, K.L., Wipf, G.C., et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res 61:5 (2001), 1934–1940.
7. [7] Parkin, D.M., Almonte, M., Bruni, L., Clifford, G., Curado, M.P., Pineros, M., Burden and trends of type-specific human papillomavirus infections and related diseases in the Latin America and Caribbean region. Vaccine 19:26 Suppl 11 (2008), L1–L15.
8. [8] Brown, D.R., Schroeder, J.M., Bryan, J.T., Stoler, M.H., Fife, K.H., Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 37:10 (1999), 3316–3322.
9. [9] Rowhani-Rahbar, A., Hawes, S.E., Sow, P.S., Toure, P., Feng, Q., Dem, A., et al. The impact of HIV status and type on the clearance of human papillomavirus infection among Senegalese women. J Infect Dis 196:6 (2007), 887–894.
10. [10] Hessol, N.A., Holly, E.A., Efird, J.T., Minkoff, H., Schowalter, K., Darragh, T.M., et al. Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women. AIDS (London, England) 23:1 (2009), 59–70.
11. [11] Meeuwis, K.A., Melchers, W.J., Bouten, H., van de Kerkhof, P.C., Hinten, F., Quint, W.G., et al. Anogenital malignancies in women after renal transplantation over 40 years in a single center. Transplantation 93:9 (2012), 914–922.
12. [12] Ogunbiyi, O.A., Scholefield, J.H., Raftery, A.T., Smith, J.H., Duffy, S., Sharp, F., et al. Prevalence of anal human papillomavirus infection and intraepithelial neoplasia in renal allograft recipients. Brit J Surg 81:3 (1994), 365–367.
13. [13] Sasadeusz, J., Kelly, H., Szer, J., Schwarer, A.P., Mitchell, H., Grigg, A., Abnormal cervical cytology in bone marrow transplant recipients. Bone Marrow Transplant 28:4 (2001), 393–397.
14. [14] Dreyer, L., Faurschou, M., Mogensen, M., Jacobsen, S., High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Arthritis Rheum 63:10 (2011), 3032–3037.
15. [15] Santana, I.U., Gomes Ado, N., Lyrio, L.D., Rios Grassi, M.F., Santiago, M.B., Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. Clin Rheumatol 30:5 (2011), 665–672.
16. [16] Liyanage, S.S., Rahman, B., Ridda, I., Newall, A.T., Tabrizi, S.N., Garland, S.M., et al. The aetiological role of human papillomavirus in oesophageal squamous cell carcinoma: a meta-analysis. PLoS ONE, 8(7), 2013, e69238.
17. [17] Department of Health. Australian Govt. Human Papillomavirus (HPV). The Program; 2015 < http://hpv.health.gov.au/the-program/> [cited 2015 26 May].
18. [18] Cancer Council Australia. The HPV vaccine; 2015 < http://www.hpvvaccine.org.au/about-the-vaccine/vaccine-background.aspx> [cited 2015 26 May].
19. [19] Donovan, B., Franklin, N., Guy, R., Grulich, A.E., Regan, D.G., Ali, H., et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 11:1 (2011 Jan), 39–44.
20. [20] Garland, S.M., The Australian experience with the human papillomavirus vaccine. Clin Ther 36:1 (2014 Jan 1), 17–23.
21. [21] Gertig, D.M., Brotherton, J.M., Budd, A.C., Drennan, K., Chappell, G., Saville, A.M., Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med, 11, 2013, 227.
22. [22] Levin, M.J., Moscicki, A.B., Song, L.Y., Fenton, T., Meyer, W.A. 3rd., Read, J.S., et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acq Imm Def Synd (1999) 55:2 (2010), 197–204.
23. [23] Weinberg, A., Song, L.Y., Saah, A., Brown, M., Moscicki, A.B., Meyer, W.A. 3rd, et al. Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. J Infect Dis 206:8 (2012), 1309–1318.
24. [24] Jacobson, D.L., Bousvaros, A., Ashworth, L., Carey, R., Shrier, L.A., Burchett, S.K., et al. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis 19:7 (2013), 1441–1449.
25. [25] Heijstek, M.W., Scherpenisse, M., Groot, N., Wulffraat, N.M., Van Der Klis, F.R., Immunogenicity of the bivalent human papillomavirus vaccine in adolescents with juvenile systemic lupus erythematosus or juvenile dermatomyositis. J Rheumatol 40:9 (2013), 1626–1627.
26. [26] Mok, C.C., Ho, L.Y., Fong, L.S., To, C.H., Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis 72:5 (2013), 659–664.
27. [27] Brown, D., Muller, M., Sehr, P., Pawlita, M., Seitz, H., Rubio, I., et al. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18. Vaccine 32:44 (2014), 5880–5887.
28. [28] Dias, D., Van Doren, J., Schlottmann, S., Kelly, S., Puchalski, D., Ruiz, W., et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 12:8 (2005), 959–969.
29. [29] Opalka, D., Lachman, C.E., MacMullen, S.A., Jansen, K.U., Smith, J.F., Chirmule, N., et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 10:1 (2003), 108–115.
30. [30] Opalka, D., Matys, K., Bojczuk, P., Green, T., Gesser, R., Saah, A., et al. Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vacc Immunol: CVI 17:5 (2010), 818–827.
31. [31] Brown, D.R., Garland, S.M., Ferris, D.G., Joura, E., Steben, M., James, M., et al. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vacc 7:2 (2011), 230–238.
32. [32] Abu-Shakra, M., Press, J., Sukenik, S., Buskila, D., Influenza virus vaccination of patients with SLE: effects on generation of autoantibodies. Clin Rheumatol 21:5 (2002), 369–372.
33. [33] Harwood, C.A., Surentheran, T., McGregor, J.M., Spink, P.J., Leigh, I.M., Breuer, J., et al. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 61:3 (2000), 289–297.
34. [34] Hippelainen, M., Syrjanen, S., Hippelainen, M., Koskela, H., Pulkkinen, J., Saarikoski, S., et al. Prevalence and risk factors of genital human papillomavirus (HPV) infections in healthy males: a study on Finnish conscripts. Sex Transm Dis 20:6 (1993), 321–328.
35. [35] Kataja, V., Syrjanen, S., Yliskoski, M., Hippelinen, M., Vayrynen, M., Saarikoski, S., et al. Risk factors associated with cervical human papillomavirus infections: a case-control study. Am J Epidemiol 138:9 (1993), 735–745.
36. [36] Tarkowski, T.A., Koumans, E.H., Sawyer, M., Pierce, A., Black, C.M., Papp, J.R., et al. Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. J Infect Dis 189:1 (2004), 46–50.
37. [37] Newall, A.T., Brotherton, J.M., Quinn, H.E., McIntyre, P.B., Backhouse, J., Gilbert, L., et al. Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clin Infect Dis: Off Publ Infect Dis Soc Am 46:11 (2008), 1647–1655.
38. [38] Block, S.L., Nolan, T., Sattler, C., Barr, E., Giacoletti, K.E., Marchant, C.D., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118:5 (2006), 2135–2145.
39. [39] Ferris, D., Samakoses, R., Block, S.L., Lazcano-Ponce, E., Restrepo, J.A., Reisinger, K.S., et al. Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics 134:3 (2014), e657–e665.
40. [40] Reisinger, K.S., Block, S.L., Lazcano-Ponce, E., Samakoses, R., Esser, M.T., Erick, J., et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 26:3 (2007), 201–209.
41. [41] Baseman, J.G., Koutsky, L.A., The epidemiology of human papillomavirus infections. J Clin Virol: Off Publ Pan Am Soc Clin Virol 32:Suppl 1 (2005), S16–S24.
42. [42] Delere, Y., Wichmann, O., Klug, S.J., van der Sande, M., Terhardt, M., Zepp, F., et al. The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta-analysis. Deut Arzteblatt Int 111:35–36 (2014), 584–591.
43. [43] Wilkin, T., Lee, J.Y., Lensing, S.Y., Stier, E.A., Goldstone, S.E., Berry, J.M., et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 202:8 (2010), 1246–1253.
44. [44] Kumar, D., Unger, E.R., Panicker, G., Medvedev, P., Wilson, L., Humar, A., Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg 13:9 (2013), 2411–2417.
45. [45] Alter, B.P., Giri, N., Pan, Y., Savage, S.A., Pinto, L.A., Antibody response to human papillomavirus vaccine in subjects with inherited bone marrow failure syndromes. Vaccine 32:10 (2014), 1169–1173.
46. [46] Hartevelt, M.M., Bavinck, J.N., Kootte, A.M., Vermeer, B.J., Vandenbroucke, J.P., Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 49:3 (1990), 506–509.
47. [47] Veness, M.J., Quinn, D.I., Ong, C.S., Keogh, A.M., Macdonald, P.S., Cooper, S.G., et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer 85:8 (1999), 1758–1764.